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Therapeutic and adverse effects of chronic oral intake of Mucuna pruriens seed extracts 
or L-DOPA methyl ester in 6-hydroxydopamine lesioned rats
Monica Jørgensen1,2, Lars Porskjær Christensen2 and Jan Bert Gramsbergen1
1Institute of Molecular Medicine; 2Institute of Chemical Engineering, Biotechnology and Environmental Technology, University of Southern Denmark, Odense
Introduction
Levodopa (L-DOPA, L-3,4-dihydroxyphenylalanine) is the most effective symptomatic agent in the 
treatment of Parkinson’s Disease (PD) as a dopamine replacement therapy. Chronic use of L-DOPA 
is, however, known to induce dyskinesias (Abnormal Involuntary Movements in rats (AIMs)) (Jenner 
2008).
Seeds of the legume Mucuna pruriens (MP) are a rich source of L-DOPA and preparations of MP 
seeds have long been used to treat PD in the traditional Ayurvedic Indian Medicine system (Singhal et 
al. 2003). It has been suggested that MP preparations induce less motor complications in PD patients 
than synthetic L-DOPA (Katzenschlager et al 2004). Methanol extraction of MP seeds (MP-MeOH) 
yields large amounts of L-DOPA (15-20%), whereas hexane extracts (MP-hex) are rich in lipophilic 
compounds like coenzyme Q10. 
Aim of study
1. To investigate, in an animal model for PD, the acute, dose-dependent therapeutic and adverse 
effects of L-DOPA methyl ester (LDME) and MP-MeOH after intraperitoneal (ip) injections. 
2. To monitor L-DOPA plasma levels in rats receiving LDME or MP-MeOH extract via the drinking 
water.
3. To study the development of adverse effect after chronic oral administration of MP-MeOH, MP-
MeOH combined with ip injections of MP-hex or LDME preparations. 
Method and materials
Animal model: unilaterally 6-hydroxydopamine (6-OHDA) lesioned male Sprague Dawley rats with 
> 98% striatal DA-depletion (left medial forebrain bundle, 8 µg 6-OHDA free base/2 µl 0.1% ascorbic 
acid)
Monitoring therapeutic and adverse effects: Cylinder test (therapeutic effects) and AIMs rating 
scale (adverse effects (dyskinesias)) (Lundblad et al 2002). 
Drug preparations: LDME or MP-MeOH solubilized in ascorbic acid solutions together with bense-
razide (15 mg benserazide/kg, for ip administration or 1 mg benserazide/ml for oral administration). 
Solutions were normalized to specific L-DOPA concentrations. MP hexane extract was administered 
daily, 250 mg/kg, ip for 3 weeks.
Blood sampling and DOPA assay: Via permanent catheter (a. femoralis). DOPA was extracted with 
perchloric acid (PCA) and determined by HPLC with electrochemical detection.
Protocol
Acute dose-dependent tests: ip administration (LDME and MP-MeOH), (3, 6, 9 mg/kg)
Pre- and post challenge tests: ip administration (LDME), (6 mg/kg)
Chronic oral treatment: 3 weeks of oral administration via drinking water (LDME, MP-MeOH, MP-
MeOH+hexan and control), (0.5-2.0 mg DOPA/ml), (MP-hex 250 mg/kg, ip)
Discussion and conclusions
Acute dose dependent tests using LDME or MP-MeOH preparations (ip adm.), showed significant 
higher AIMs scores with increasing dose (***, p<0.001), with no difference between LDME and MP-
MeOH preparations. AIMs were observed even at low dose (3 mg/kg) in both groups. The therapeutic 
effect was achieved with 6 mg DOPA/kg for MP-MeOH treated rats, but in LDME-treated rats this 
dose caused severe AIMs interfering with normal forelimb use. 
Oral treatment via the drinking water caused large variations in plasma DOPA levels between mor-
ning and afternoon, but similar average plasma levels in LDME- and MP-MeOH-treated rats. A weak 
relation (*, p<0.05, r2=0.337) was observed between the average amount of DOPA intake and the 
averaged total AIMs score. 
Chronic oral treatment with LDME, MP-MeOH or MP-MeOH+hexane showed no significant differen-
ces in AIMs scores following a LDME challenge test (ip). However within treatment groups, pre- and 
post challenge tests did not show significant differences either, in contrast to chronic ip administration. 
Figure 4
Seeds from Mucuna pruriens, the plants, pods and flowers
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Figure 1
 (A) Acute dose-dependent AIMs score after ip administration 
of MP-MeOH or LDME preparations (60 min post injection). 
Results are shown as mean ± SEM (LDME group: n=13-15; 
MP-MeOH group: n=13-16). 
*** p<0.001, ANOVA with Bonferroni post-test
(B) Acute dose-dependent test of therapeutic effects af-
ter ip administration of MP-MeOH or LDME preparations 
(60 min post injection). Results are shown as mean ± SEM 
(BL=baseline groups: n=15-16; LDME group n=4-12, except 
LDME 9 mg/kg: no observations; MP-MeOH group: n=6-14, 
except MP-MeOH 9 mg/kg: n=2. Unequal number of obser-
vations is due to dyskinetic animals. 
** p<0.01, ANOVA with Bonferroni post-test 
Figure 2 
(A) Acute observed AIMs after ip administration of LDME (6 
mg/kg) in different treatment groups, pre- and post chronic 
oral treatment via the drinking water. Results are shown as 
mean ± SEM. For all groups n=4. 
(B) Therapeutic effects at different DOPA doses administered 
via the drinking water. Results are shown as mean ± SEM 
(n=6-14). 
** p<0.01, ANOVA with Bonferroni post-test
Figure 3 
(A) DOPA intake (mg) via drinking water and observed av-
erage total AIMs score in LDME-treated rats. Results are 
shown as the mean DOPA intake in one home cage with 4 
rats, measured by weight and mean total AIMs score ± SEM 
(n=4).
* p<0.05, r2=0.337, linear regression (Goodness of Fit). 
(B) Plasma DOPA levels after oral administration of LDME 
or MP-MeOH via the drinking water. Blood sampling was 
performed at various time points during the day. Results are 
shown as mean ± SEM. n=4-9, except LDME 1 mg/ml (7am): 
n=18 
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